Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selicrelumab +/- Chemo in Resectable Pancreatic Cancer
NCT02588443Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of selicrelumab in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Oct 2015; status: completed.
02
Drugs
selicrelumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02588443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588443.